Summary of studies describing the management of CML diagnosed in pregnancy
| Study . | N . | Treatment during pregnancy (n, %) . | Outcome (n, %) . | TKI after pregnancy end (n, %) . | ≥MMR, n (%) . | Adverse disease outcomes (n, %) . |
|---|---|---|---|---|---|---|
| Assi et al9 | 15 | HC (5, 33) IFN (3, 20) Leukapheresis (1, 7) Nilotinib (1, 7) Observation (5, 33) | Live birth (12, 80) Spontaneous termination (2, 13) Elective termination (1, 7) | Imatinib (4, 27) Dasatinib (6, 40) Nilotinib (5, 33) | 14 (93) | Blast crisis and death (1, 7) |
| Chelysheva et al10 | 48 | Imatinib (10, 30) IFN only (2, 6) IFN + imatinib (3, 10) HC (4, 12) Observation (14, 42)a | Live birth (33, 71) Spontaneous termination (1, 2) Elective termination (14, 29) | Imatinib (30, 94) Nilotinib (1, 2) Dasatinib (1, 2)a,b | 17 (52)a | Blast crisis and death (2, 6)a |
| aDenominator derived from the number of patients who continued pregnancy to term (n = 33). | ||||||
| bOne patient had a set of twins, analyzed as 2 pregnancies. | ||||||
| Study . | N . | Treatment during pregnancy (n, %) . | Outcome (n, %) . | TKI after pregnancy end (n, %) . | ≥MMR, n (%) . | Adverse disease outcomes (n, %) . |
|---|---|---|---|---|---|---|
| Assi et al9 | 15 | HC (5, 33) IFN (3, 20) Leukapheresis (1, 7) Nilotinib (1, 7) Observation (5, 33) | Live birth (12, 80) Spontaneous termination (2, 13) Elective termination (1, 7) | Imatinib (4, 27) Dasatinib (6, 40) Nilotinib (5, 33) | 14 (93) | Blast crisis and death (1, 7) |
| Chelysheva et al10 | 48 | Imatinib (10, 30) IFN only (2, 6) IFN + imatinib (3, 10) HC (4, 12) Observation (14, 42)a | Live birth (33, 71) Spontaneous termination (1, 2) Elective termination (14, 29) | Imatinib (30, 94) Nilotinib (1, 2) Dasatinib (1, 2)a,b | 17 (52)a | Blast crisis and death (2, 6)a |
| aDenominator derived from the number of patients who continued pregnancy to term (n = 33). | ||||||
| bOne patient had a set of twins, analyzed as 2 pregnancies. | ||||||